Skip to content

Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease

Can a Sick-Day Protocol to Improve Outcomes in Chronic Kidney Disease?

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03141905
Enrollment
342
Registered
2017-05-05
Start date
2017-10-16
Completion date
2020-10-07
Last updated
2021-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Diseases, Safety Issues

Keywords

patient safety, self-management, remote monitoring

Brief summary

The benefits of renin angiotensin system (RAS) blockers and diuretics for blood pressure control are well-established in chronic kidney diseases (CKD) patients; however, these agents may become hazardous on sick-days that lead to volume depletion (dehydration), and increase the risk of kidney function loss and acute kidney injury (AKI). It is not known how frequent significant sick-days occur in CKD patients, or whether a patient self-managed Sick-Day Protocol (SDP) that temporarily holds RAS blocker, diuretics, or other high risk medication in an effort to preserve renal function, or prevent AKI. The purpose of the study is to asses if a SDP, monitored remotely with a weekly automated phone survey , can improve outcomes in CKD (such as slow renal function loss and AKI episodes) and reduce preventable service utilization versus usual care.

Detailed description

Hypothesis: implementing a self managed Sick-Day Protocol with telephone monitoring via interactive voice survey dial-response system (IVSDRS) in CKD patients taking RAS blockers, diuretics, metformin, or NSAIDs, will safely slow renal function loss, reduce the incidence of acute kidney injury, and prevent urgent health utilization; in comparison to usual care. Study Design: 6-month randomized trial of Sick-Day Protocol vs usual care Randomization: In-block randomization stratified by use (with or without any other qualifying medication) vs non-use of RAS blocker (with any other qualifying medication) Intervention: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness), IVRSDRS remote monitoring, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC) Study Population: Veterans across the VA Maryland Health Care System (VAMCHS) with a current prescription for any type of RAS blocker, Diuretic, Metformin or NSAID. Study Site: Baltimore VA Medical Center (BVAMC), VA Geriatrics Research Education and Clinical Center (GRECC). Specific Aims 1: Conduct a pragmatic trial comparing the renal function decline, incidence of AKI, and urgent service utilization in eligible CKD patients provided with a self-managed Sick-Day Protocol versus comparable patients receiving usual care.Specific Aim 2: Determine the incidence of sick-days in the intervention arm using remote IVSDRS monitoring and end-of-study survey of all participants. Specific Aim 3: Evaluate intervention arm participants' usage of, and adherence to, the Sick-Day Protocol with remote IVSDRS monitoring. Study Measurements: laboratory-measured renal function, and patient- reported safety events obtained per IVSDRS protocol. Emergency department (ED) visits, hospitalization, renal progression, incidence of ESRD, and death will be measured in both groups along with patient satisfaction. Primary outcomes: 6-month change in renal function (eGFR), incidence of AKI episodes (including ICD-10 code designated, and detectable creatinine-based changes in renal function usingRIFLE criteria), preventable/urgent service utilization (to be ascertained using VA EHR review) Secondary outcomes: Determination of incidence of sick-day events (IVSDRS reporting, and end-of-study self-report). Tertiary:Adherence to self-management Sick-Day Protocol (based on IVSDRS reporting) Analytic plans: Comparison between intervention and usual care participants of 6-month renal function change, and frequency of AKI and hospitalization using generalized linear models and Poisson regression methods, respectively. Similar regression methods will be used to determine the adjusted frequency rate of sick-day incidents and participant response to sick-days. Public Health Relevance: Introduction of a self-management Sick-Day Protocol in conjunction with coordinated care and IVSDRS surveillance can be an innovative strategy to improve renal outcomes and reduce preventable service utilization.

Interventions

OTHERSick-Day Protocol

Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring

OTHERUsual Care

Standard clinical care

Sponsors

University of Maryland, Baltimore
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Veterans with prescription for any type of RAS blocker, diuretic, Metformin or NSAID

Exclusion criteria

* Expected death or dialysis within 6 months * No home or cellular telephone

Design outcomes

Primary

MeasureTime frameDescription
Change in Renal Function From Baseline to Study Completion;6 months (enrollment to study completion)Laboratory measurement of creatinine at study entry and completion

Secondary

MeasureTime frameDescription
Acute Kidney Injury Incidents6 months (enrollment to study completion)Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria
ER Use and Hospitalization6 months (enrollment to study completion)Participants with urgent service utilization including emergency department, hospitalization, and urgent care.

Other

MeasureTime frameDescription
Determination of Sick-day Incidents6 months from enrollment in studyParticipants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.
Adherence to the Self-management Sick-day Protocol6 months (enrollment to study completion)Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)

Countries

United States

Participant flow

Participants by arm

ArmCount
Sick-Day Protocol
Sick-Day Protocol: Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
159
Usual Care
Usual Care: Standard clinical care
156
Total315

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyDeath32
Overall StudyLost to Follow-up37
Overall StudyRandomized, but did not receive intervention. Withdrew prior to baseline visit.1710
Overall StudyWithdrawal by Subject10

Baseline characteristics

CharacteristicSick-Day ProtocolUsual CareTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
130 Participants119 Participants249 Participants
Age, Categorical
Between 18 and 65 years
29 Participants37 Participants66 Participants
eGFR43.110 ml/min/1.73m^2
STANDARD_DEVIATION 13.128
43.783 ml/min/1.73m^2
STANDARD_DEVIATION 13.018
43.441 ml/min/1.73m^2
STANDARD_DEVIATION 13.057
Ethnicity (NIH/OMB)
Hispanic or Latino
1 Participants1 Participants2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
158 Participants155 Participants313 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Asian
0 Participants1 Participants1 Participants
Race (NIH/OMB)
Black or African American
100 Participants99 Participants199 Participants
Race (NIH/OMB)
More than one race
0 Participants0 Participants0 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
1 Participants0 Participants1 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants0 Participants0 Participants
Race (NIH/OMB)
White
58 Participants56 Participants114 Participants
Region of Enrollment
United States
159 participants156 participants315 participants
Sex: Female, Male
Female
7 Participants7 Participants14 Participants
Sex: Female, Male
Male
152 Participants149 Participants301 Participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
3 / 1592 / 156
other
Total, other adverse events
7 / 1593 / 156
serious
Total, serious adverse events
0 / 1590 / 156

Outcome results

Primary

Change in Renal Function From Baseline to Study Completion;

Laboratory measurement of creatinine at study entry and completion

Time frame: 6 months (enrollment to study completion)

Population: 280 participants with complete laboratory data collection

ArmMeasureValue (MEDIAN)
Sick-Day ProtocolChange in Renal Function From Baseline to Study Completion;0.01 mg/dL
Usual CareChange in Renal Function From Baseline to Study Completion;0.02 mg/dL
Secondary

Acute Kidney Injury Incidents

Participants with abrupt changes in renal function as determined by EHR post-study review of new AKI ICD-10 codes, and for-cause lab ambulatory lab testing using RIFLE criteria

Time frame: 6 months (enrollment to study completion)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Sick-Day ProtocolAcute Kidney Injury IncidentsAKI ICD-10 code on ED visit or admission4 Participants
Sick-Day ProtocolAcute Kidney Injury Incidents50% increase in Creatinine1 Participants
Usual CareAcute Kidney Injury IncidentsAKI ICD-10 code on ED visit or admission4 Participants
Usual CareAcute Kidney Injury Incidents50% increase in Creatinine0 Participants
Secondary

ER Use and Hospitalization

Participants with urgent service utilization including emergency department, hospitalization, and urgent care.

Time frame: 6 months (enrollment to study completion)

ArmMeasureGroupValue (COUNT_OF_PARTICIPANTS)
Sick-Day ProtocolER Use and HospitalizationHospitalization29 Participants
Sick-Day ProtocolER Use and HospitalizationEmergency Room35 Participants
Sick-Day ProtocolER Use and HospitalizationUrgent Care5 Participants
Usual CareER Use and HospitalizationHospitalization23 Participants
Usual CareER Use and HospitalizationEmergency Room30 Participants
Usual CareER Use and HospitalizationUrgent Care5 Participants
Other Pre-specified

Adherence to the Self-management Sick-day Protocol

Frequency of Sick-Day qualifying illnesses reported. (Note: this outcome is N/A for the usual care group)

Time frame: 6 months (enrollment to study completion)

Population: Sick-Day Protocol group

ArmMeasureGroupValue (NUMBER)
Sick-Day ProtocolAdherence to the Self-management Sick-day ProtocolFollowed Sick-Day Protocol instructions14 count of qualifying illnesses
Sick-Day ProtocolAdherence to the Self-management Sick-day ProtocolDid not stop medicines12 count of qualifying illnesses
Sick-Day ProtocolAdherence to the Self-management Sick-day ProtocolStopped other medicines in addition to SDP qualifying.6 count of qualifying illnesses
Other Pre-specified

Determination of Sick-day Incidents

Participants reporting sick-days via IVSDRS and end-of study visit survey ascertainment.

Time frame: 6 months from enrollment in study

Population: 299 participants who completed all study visits.

ArmMeasureValue (COUNT_OF_PARTICIPANTS)
Sick-Day ProtocolDetermination of Sick-day Incidents29 Participants
Usual CareDetermination of Sick-day Incidents20 Participants

Source: ClinicalTrials.gov · Data processed: Feb 14, 2026